ProfoundBio takeout shines a light on Sutro
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
Gritstone fails to convince
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Xilio gets a Gilead-shaped reprieve
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.
Venture-backed biotechs push into the clinic
The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.
